Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31003114 | 0.88 | MAPT (0.46) | NAMPTHRH3ACACBGPR119 | |
| SCHEMBL10258571 | 0.84 | HRH3 (0.47) | NAMPTHRH3GPR119 | |
| SCHEMBL795847 | 0.82 | MAPT (0.49) | TDO2SCN1ASCN2ASCN3AHRH3 | |
| SCHEMBL30102016 | 0.81 | GPR119 (0.64) | HRH3GPR119 | |
| SCHEMBL1372747 | 0.81 | GPR119 (0.64) | HRH3GPR119 | |
| SCHEMBL1480727 | 0.78 | HRH3 (0.56) | SCN1ASCN2ASCN3AHRH3HDAC3 | |
| SCHEMBL13432215 | 0.78 | TDO2 (0.50) | TDO2NAMPTSCN1ASCN2ASCN3A | |
| SCHEMBL796507 | 0.77 | HRH3 (0.49) | SCN1ASCN2ASCN3AHRH3ACACB | |
| SCHEMBL10196809 | 0.77 | GPR119 (0.41) | TDO2NAMPTSCN1ASCN2ASCN3A | |
| SCHEMBL25918298 | 0.77 | PRMT5 (0.39) | TDO2SCN1ASCN2ASCN3AMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8247414-B2 | Pyridizinone derivatives and the use thereof as H3 inhibitors | CEPHALON, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8207168-B2 | Pyridazinone derivatives | CEPHALON, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110288075-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | TDO2 1144/4885NAMPT 307/4885SCN1A 2608/4885 |
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | TDO2 117/4885NAMPT 1159/4885SCN1A 2990/4885 |
| US-20110288075-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | TDO2 130/4885NAMPT 1318/4885SCN1A 2952/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | TDO2 119/4885NAMPT 1257/4885SCN1A 2903/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | TDO2 117/4885NAMPT 1159/4885SCN1A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.